HPV16 E7 (86-93) (TFA)
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA) -A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas[1][2].
Product Specifications
UNSPSC
12352209
Target
HPV
Type
Peptides
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/hpv16-e7-86-93-tfa.html
Purity
98.01
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 6.67 mg/mL (ultrasonic)
Smiles
CC[C@H](C)[C@@H](C(O)=O)NC([C@H]1N(C([C@H](CS)NC([C@H](C(C)C)NC([C@H]([C@@H](C)CC)NC(CNC([C@H](CC(C)C)NC([C@H]([C@H](O)C)N)=O)=O)=O)=O)=O)=O)CCC1)=O.OC(C(F)(F)F)=O
Molecular Formula
C39H67F3N8O12S
Molecular Weight
929.06
References & Citations
[1]Hoffmann TK, et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer. 2006 Apr 15;118 (8) :1984-91.|[2]Cheng WF, et al. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology. 2005 May;115 (1) :136-49.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
